Literature DB >> 17689885

Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma.

Min Yao1, Lucy H Karnell, Gerry F Funk, Heming Lu, Ken Dornfeld, John M Buatti.   

Abstract

PURPOSE: To compare health-related quality-of-life (HRQOL) outcomes of patients with oropharyngeal squamous cell carcinoma treated using intensity-modulated radiotherapy (IMRT) vs. conventional radiotherapy (CRT). PATIENTS AND METHODS: Patients with oropharyngeal squamous cell carcinoma were extracted from the database of an ongoing longitudinal Outcome Assessment Project. Eligible criteria included (1) treated with definitive radiation, and (2) provided 12-month posttreatment HRQOL data. Excluded were 7 patients who received IMRT before October 1, 2002, during this institution's developmental phase of the IMRT technique. The HRQOL outcomes of patients treated with IMRT were compared with those of patients who received CRT.
RESULTS: Twenty-six patients treated using IMRT and 27 patients treated using CRT were included. Patients in the IMRT group were older and had more advanced-stage diseases and more patients received concurrent chemotherapy. However, the IMRT group had higher mean Head and Neck Cancer Inventory scores (which represent better outcomes) for each of the four head-and-neck cancer-specific domains, including eating, speech, aesthetics, and social disruption, at 12 months after treatment. A significantly greater percentage of patients in the CRT group had restricted diets compared with those in the IMRT group (48.0% vs. 16.0%, p = 0.032). At 3 months after treatment, both groups had significant decreases from pretreatment eating scores. However, the IMRT group had a significant improvement during the first year, but the CRT group had only small improvement.
CONCLUSIONS: Proper delivery of IMRT can improve HRQOL for patients with oropharyngeal cancer compared with CRT.

Entities:  

Mesh:

Year:  2007        PMID: 17689885     DOI: 10.1016/j.ijrobp.2007.05.003

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

Review 1.  Clinical application of intensity-modulated radiotherapy for head and neck cancer.

Authors:  O Ballivy; R Galiana Santamaría; A Lozano Borbalas; F Guedea Edo
Journal:  Clin Transl Oncol       Date:  2008-07       Impact factor: 3.405

2.  Neighborhood deprivation and clinical outcomes among head and neck cancer patients.

Authors:  Lorraine R Reitzel; Nga Nguyen; Mark E Zafereo; Guojun Li; Qingyi Wei; Erich M Sturgis
Journal:  Health Place       Date:  2012-03-14       Impact factor: 4.078

3.  Adaptive radiotherapy for head-and-neck cancer: initial clinical outcomes from a prospective trial.

Authors:  David L Schwartz; Adam S Garden; Jimmy Thomas; Yipei Chen; Yongbin Zhang; Jan Lewin; Mark S Chambers; Lei Dong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-02       Impact factor: 7.038

4.  Comparison of acute toxicities in two primary chemoradiation regimens in the treatment of advanced head and neck squamous cell carcinoma.

Authors:  Katherine Y Fan; Hrishikesh Gogineni; David Zaboli; Spencer Lake; Marianna L Zahurak; Simon R Best; Marshall A Levine; Mei Tang; Eva S Zinreich; John R Saunders; Joseph A Califano; Ray G Blanco; Sara I Pai; Barbara Messing; Patrick K Ha
Journal:  Ann Surg Oncol       Date:  2012-06       Impact factor: 5.344

5.  Phase II trial of hyperfractionated intensity-modulated radiation therapy and concurrent weekly cisplatin for Stage III and IVa head-and-neck cancer.

Authors:  Patrick D Maguire; Michael Papagikos; Sue Hamann; Charles Neal; Martin Meyerson; Neil Hayes; Peter Ungaro; Kenneth Kotz; Marion Couch; Hoke Pollock; Joel Tepper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-08       Impact factor: 7.038

Review 6.  Quality of life in oropharyngeal cancer: a structured review of the literature.

Authors:  Evelyne Roets; Karina Tukanova; Anouk Govarts; Pol Specenier
Journal:  Support Care Cancer       Date:  2018-05-03       Impact factor: 3.603

7.  Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.

Authors:  Nancy Lee; Sadek Nehmeh; Heiko Schöder; Matthew Fury; Kelvin Chan; C Clifton Ling; John Humm
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-07       Impact factor: 7.038

Review 8.  Application of fluorodeoxyglucose positron emission tomography in the management of head and neck cancers.

Authors:  Farzan Siddiqui; Min Yao
Journal:  World J Radiol       Date:  2014-06-28

9.  Physician perspective on incorporation of oncology patient quality-of-life, fatigue, and pain assessment into clinical practice.

Authors:  Joleen M Hubbard; Axel F Grothey; Robert R McWilliams; Jan C Buckner; Jeff A Sloan
Journal:  J Oncol Pract       Date:  2014-03-25       Impact factor: 3.840

10.  Standard chemoradiation versus intensity-modulated chemoradiation: a quality of life assessment in oropharyngeal cancer patients.

Authors:  Sarah E Mowry; Christopher Tang; Ahmad Sadeghi; Marilene B Wang
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-12-29       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.